How should management (staging, systemic therapy, trials) change for patients with high‑grade prostate cancer and very low PSA?
(Grade Group 4–5 or Gleason ≥8) with a deceptively low serum PSA should trigger more aggressive staging and consideration of treatment intensification rather than reassurance; modern imaging (includin...